GlassScriptPhysician profile
Bryan L Dalton
NPI 1386647428
$531.22
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.57 · 2020: $61.52 · 2021: $357 · 2023: $17.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $145.20 | 2021 | |
| Novo Nordisk INC | $45.58 | 2020-2021 | |
| Nevro Corp. | $43.04 | 2021 | |
| Lilly USA, LLC | $38.88 | 2019-2021 | |
| Amgen INC. | $38.14 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.02 | 2021 | |
| Alk-Abello, INC | $24.45 | 2019 | |
| Sanofi Pasteur INC. | $18.73 | 2021 | |
| Allergan, INC. | $17.82 | 2019 | |
| Abbvie INC. | $17.19 | 2023 | Qulipta |
| Glaxosmithkline, LLC. | $16.09 | 2020 | |
| Astellas Pharma US INC | $13.02 | 2021 | |
| Amarin Pharma, INC. | $12.86 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.